Legend Biotech (LEGN) Cash from Investing Activities (2019 - 2025)

Legend Biotech's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $638.5 million for Q4 2025.

• Quarterly Cash from Investing Activities rose 826.39% year-over-year to $638.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $709.6 million (up 183.42% YoY) and the FY2025 annual result came in at $709.6 million, up 183.42% from the prior year.
• Cash from Investing Activities was $638.5 million for Q4 2025 at Legend Biotech, up from -$20.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $638.5 million in Q4 2025 and bottomed at -$695.6 million in Q2 2024.
• A 5-year average of -$30.6 million and a median of -$54.0 million in 2024 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 1534.48% in 2023, while the deepest fall reached 4807.27% in 2023.
• Legend Biotech's Cash from Investing Activities stood at -$195.0 million in 2021, then jumped by 112.79% to $24.9 million in 2022, then jumped by 1534.48% to $407.5 million in 2023, then plunged by 121.57% to -$87.9 million in 2024, then soared by 826.39% to $638.5 million in 2025.
• Business Quant data shows LEGN's Cash from Investing Activities at $638.5 million in Q4 2025, -$20.0 million in Q3 2025, and -$165.5 million in Q2 2025.